A randomized controlled phase II trial of riluzole in early multiple sclerosis (Q34286809)

1 August 2017

A randomized controlled phase II trial of riluzole in early multiple sclerosis (English)

1 reference

1 August 2017

phase II clinical trial

0 references

0 references

1

Emmanuelle Waubant

1 reference

1 August 2017

Amir-Hadi Maghzi

2

1 reference

1 August 2017

Nisha Revirajan

3

1 reference

1 August 2017

Rebecca Spain

4

1 reference

1 August 2017

Laura Julian

5

1 reference

1 August 2017

Ellen M Mowry

6

1 reference

1 August 2017

Jacqueline Marcus

7

1 reference

1 August 2017

Shuang Liu

8

1 reference

1 August 2017

Chengshi Jin

9

1 reference

1 August 2017

Ari Green

10

1 reference

1 August 2017

Charles E McCulloch

11

1 reference

1 August 2017

Daniel Pelletier

12

1 reference

1 August 2017

14 April 2014

1 reference

Annals of clinical and translational neurology

1 August 2017

1 reference

1 August 2017

1

1 reference

1 August 2017

340-347

1 reference

1 August 2017

5

1 reference

Molecular mechanisms linking neuroinflammation and neurodegeneration in MS.

1 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4184685

Clinical relevance of brain volume measures in multiple sclerosis

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4184685

Neuroprotection in multiple sclerosis: a therapeutic approach

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4184685

EDSS variability before randomization may limit treatment discovery in primary progressive MS.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4184685

Randomized controlled trial of atorvastatin in clinically isolated syndrome: the STAyCIS study

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4184685

Color vision is strongly associated with retinal thinning in multiple sclerosis.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4184685

Lamotrigine for neuroprotection in secondary progressive multiple sclerosis: a randomised, double-blind, placebo-controlled, parallel-group trial.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4184685

Quality of life in multiple sclerosis is associated with lesion burden and brain volume measures

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4184685

Rate of brain atrophy in benign vs early multiple sclerosis.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4184685

Gray matter atrophy in multiple sclerosis: a longitudinal study

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4184685

MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4184685

Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4184685

Glutamate inhibition in MS: the neuroprotective properties of riluzole

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4184685

Advances in functional and structural MR image analysis and implementation as FSL

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4184685

Glutamate uptake by oligodendrocytes: Implications for excitotoxicity in multiple sclerosis

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4184685

Accurate, robust, and automated longitudinal and cross-sectional brain change analysis

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4184685

Segmentation of brain MR images through a hidden Markov random field model and the expectation-maximization algorithm

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4184685

Multiple sclerosis: altered glutamate homeostasis in lesions correlates with oligodendrocyte and axonal damage

6 July 2018

1 reference

Riluzole suppresses experimental autoimmune encephalomyelitis: implications for the treatment of multiple sclerosis

21 January 2018

1 reference

The effect of the neuroprotective agent riluzole on MRI parameters in primary progressive multiple sclerosis: a pilot study

21 January 2018

1 reference

Riluzole in cerebellar ataxia: a randomized, double-blind, placebo-controlled pilot trial

21 January 2018

1 reference

Normalized accurate measurement of longitudinal brain change.

21 January 2018

1 reference

A randomized, double-blind, phase 2 study of erythropoietin in optic neuritis.

21 January 2018

1 reference

Glutamate excitotoxicity in a model of multiple sclerosis

21 January 2018

1 reference

12 December 2020

Gray matter atrophy is related to long-term disability in multiple sclerosis

1 reference

12 December 2020

Riluzole promotes survival of rat motoneurons in vitro by stimulating trophic activity produced by spinal astrocyte monolayers

1 reference

12 December 2020

A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group

1 reference

12 December 2020

Autoimmune encephalomyelitis ameliorated by AMPA antagonists

1 reference

12 December 2020

Identifiers

DOI

10.1002/ACN3.60

1 reference

1 August 2017

1 reference

1 August 2017

1 reference